Skip to main content
. Author manuscript; available in PMC: 2016 Mar 1.
Published in final edited form as: J Bone Miner Res. 2015 Mar;30(3):481–488. doi: 10.1002/jbmr.2364

Fig. 4.

Fig. 4

MSDC-0602 does not affect bone. Six-month-old mice were fed native chow or that supplemented with rosiglitazone or MSDC-0602. All determinations were made after 6 months. (A) Whole-body BMD. (B) μCT image of distal femur. (C) μCT determination of BV/TV, trabecular number, trabecular thickness, and trabecular separation of distal femoral. (D) TRAP-stained histological sections of proximal tibia of control, rosiglitazone-treated, and MSDC-0602-treated mice. (E) Histomorphometrically determined BV/TV, total number of osteoclasts normalized to bone surface (Oc.N/BS), the percentage of bone surface to which osteoclasts are juxtaposed (Oc.S/BS), and adipocyte number/field. (F–H) Mice were administered time-spaced courses of calcein and alizarin. Bone formation rate (BFR) and mineral apposition rate (MAR) were histomorphometrically quantitated. (I) Serum osteocalcin determination. White bars = control; gray bars = rosiglitazone; black bars = MSDC-0602. **p < 0.01 versus control; *p < 0.05 versus control; ##p < 0.01 versus rosiglitazone; #p < 0.05 versus <zaq;3>. Scale bars = 1 mm (B); 500 μm (D, top panels); 50 μm (D, bottom panels, and F).